Clinical Trial Update: Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for Zanzalintinib (XL092) in combination with immunotherapy for advanced or metastatic renal cell carcinoma, including t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Zanzalintinib (XL092) (Zanzalintinib)

Snippet

Sponsor: Karie Runcie | Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Status: RECRUITING